Brevan Howard Capital Management
ARCT icon

Brevan Howard Capital Management’s Arcturus Therapeutics ARCT Stock Holding History

Brevan Howard Capital Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$193K Sell
28,762
-3,982
-12% -$31.4K ﹤0.01% 1913
2026
Q1 		$253K Buy
32,744
+8,064
+33% +$58.8K ﹤0.01% 1743
2025
Q4 		$151K Sell
24,680
-3,416
-12% -$36.9K ﹤0.01% 1632
2025
Q3 		$518K Buy
+28,096
New +$451K ﹤0.01% 1273
2025
Q1 		– Sell
-12,305
Closed -$209K – 1150
2024
Q4 		$209K Buy
12,305
+1,486
+14% +$28K ﹤0.01% 899
2024
Q3 		$251K Buy
+10,819
New +$231K ﹤0.01% 923
2024
Q1 		– Sell
-6,749
Closed -$213K – 1002
2023
Q4 		$213K Buy
+6,749
New +$160K ﹤0.01% 864

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Brevan Howard Capital Management's ARCT Position: Q2 2026 in Review

Brevan Howard Capital Management reduced its Arcturus Therapeutics (ARCT) stake by 12% in Q2 2026, selling an estimated $31.4K and leaving 28,762 shares worth $193K. The position accounts for ﹤0.01% of the portfolio, ranked #1913.

Brevan Howard Capital Management first reported a position in ARCT in Q4 2023 and has held it in 7 quarters since. The position peaked at $518K in Q3 2025. 135 funds tracked by Wall St. Rank hold ARCT as of Q2 2026.

  • Brevan Howard Capital Management held 28,762 shares of Arcturus Therapeutics worth $193K as of Q2 2026.
  • Brevan Howard Capital Management sold 3,982 Arcturus Therapeutics shares in Q2 2026, an estimated $31.4K.
  • Arcturus Therapeutics made up ﹤0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1913 holding.
  • Brevan Howard Capital Management first reported a position in Arcturus Therapeutics in Q4 2023 and has held it in 7 quarters since.
  • Brevan Howard Capital Management's Arcturus Therapeutics position peaked at $518K in Q3 2025.
  • 135 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.